U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Drug Supply Chain Integrity
  5. FDA Issues Letters to Doctors Who May Have Purchased Counterfeit or Unapproved Prescription Drugs
  1. Drug Supply Chain Integrity

FDA Issues Letters to Doctors Who May Have Purchased Counterfeit or Unapproved Prescription Drugs

For years FDA has responded to several breaches in the U.S. drug supply chain by rogue distributors who target doctors' offices and clinics offering unapproved, counterfeit, or otherwise unsafe prescription drugs. Doctors who purchase and administer these drugs are putting their patients at risk because these drugs may:

  • Be fake, contaminated, ineffective, or otherwise unsafe;
  • Not have been evaluated by FDA for safety and efficacy;
  • Not contain the appropriate amount of active ingredients; or
  • Contain harmful ingredients.

To reduce the public health threat posed by these potentially dangerous drugs FDA issues letters to inform doctors that may have obtained counterfeit or unapproved drugs from a rogue distributor, and provide tips on safe purchasing practices. For information on safe purchasing practices, see FDA’s Know Your Source campaign.

Under the Drug Supply Chain Security Act, as of January 1, 2015, all health care providers who dispense or administer prescription drugs to patients are required to purchase their prescription drug products only from authorized trading partners licensed by or registered with the state or federal government, as applicable. This will help ennsure that these prescription drugs are purchased from legitimate sources who are subject to oversight by the state or federal government.  To verify a wholesale drug distributor is licensed in the state(s) where it is conducting business, see Verify Wholesale Drug Distributor Licenses.

FDA encourages health care professionals to report any suspected criminal activity to FDA’s Office of Criminal Investigations (OCI)

Counterfeit Botox Distributed by TC Medical

On March 21, 2016, FDA issued more than 1,300 letters to medical practices in the United States that purchased unapproved prescription drugs and/or injectable devices from TC Medical, an unlicensed supplier that distributed counterfeit Botox found in the United States. On May 7, 2015, TC Medical pleaded guilty to orchestrating a multi-year conspiracy to smuggle misbranded prescription products into the United States.

On March 30, 2016, FDA issued approximately 100 letters to medical practices in the United States that purchased from TC Medical and had also purchased from a different unlicensed distributor previously. On that same date, FDA also issued a letter to one U.S. doctor who purchased from TC Medical and who had also purchased from two other unlicensed distributors previously.

Criminal Cases

Back to Top

More than 39 Unapproved Drugs Purchased from Gallant Pharmaceutical International or Gallant Medical International

On April 1, 2015, FDA sent more than 300 letters to medical practices in the United States that may have purchased unapproved prescription drugs, or unapproved/uncleared injectable devices, from a foreign supplier, Gallant Pharmaceutical International, Inc., also known as Gallant Medical International, Inc. Several individuals associated with Gallant, including a doctor and an office manager, have been convicted for their roles in distributing illegal drugs and devices.

Criminal Cases

Back to Top

Back to Top